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Background: Human papillomavirus type 16 (HPV16) infection is implicated in cervical carcinogenesis. This study
aimed to characterize two new monoclonal antibodies (mAbs) against HPV L1 protein.
Methods: The immunocompetence of AE3 and AG7 mAbs for HPV L1 protein was evaluated by Western blot
analysis, immunostaining, hemagglutination inhibition assay, and ELISA. The heavy chain variable region (VH) and
light chain variable region (VL) of AE3 and AG7 mAbs were sequenced and analyzed.
Results: Both mAbs specifically recognized HPV16 L1 and virus-like particles (VLPs). Both the affinity and the titer of
AE3 mAb were higher than that of AG7. There were differences in sequences in the complementary determining
regions (CDR) 2 and 3 of VL, as well as in the CDR1 and CDR3 of VH. The two mAbs have distinct predicted
three-dimensional structures.
Conclusions: We characterized two mAbs neutralizing antibodies for HPV L1 protein, which would help develop
genetic-engineered neutralizing antibodies against HPV16 for diagnostic and therapeutic purposes.
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Human papillomaviruses (HPVs) are non-enveloped,
epitheliotropic viruses that mainly cause abnormal
hyperplasia in the skin and mucosa. HPVs are related
to a variety of benign and malignant lesions [1]. HPV
type 16 (HPV16) has been found as a high risk of car-
cinogenesis [2-4].
Numerous studies have been preformed to develop
HPV vaccine [5]. However, current HPV vaccine fails to
completely prevent against cervical cancer as the cer-
vical cancer is related to more than 15 types of HPV in-
fection [6]. Early diagnosis and treatment of high risk
HPV-infection that may induce pathological changes are
still keys to control cervical cancer and precancerous* Correspondence: Hxgu2432@163.com; weilanlan1119@163.com
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unless otherwise stated.lesions [7,8]. Neutralizing antibodies against HPV L1 pro-
tein have shown promise in the prevention of cervical can-
cer [9]. The L1 gene of HPV is well-conserved and
encodes a major structural protein of HPV16. The L1 pro-
tein contains a number of epitopes that can induce the
production of specific neutralizing antibodies against HPV
[10,11]. Therefore, the generation and selection of highly
efficient anti-HPV L1 monoclonal antibodies (mAbs) are
crucial for the clinical diagnosis and treatment of HPV
infection.
In this study, the recombinant HPV16 L1 protein
was used as an antigen to generate two mAbs. To
analyze the differences in these two mAbs, the se-
quences of heavy chain variable region (VH) and
light chain variable region (VL) were determined and
compared between two mAbs. Our results provide
important information on the development of HPV
neutralizing antibodies.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Preparation of mAbs
Generation of recombinant HPV16 L1 protein was
induced by isopropy-β-D-thiogalactoside (IPTG) from
pQE31-HPV16L1/M15 constructed in our laboratory.
Purified protein was used to immunize BALB/c mice,
and two hybridoma cell lines (AE3 and AG7) were se-
lected which stably expressed neutralizing antibodies
against HPV16 L1 protein. The culture supernatant
and ascites from mice carrying AE3 and AG7 hybridomas
were purified by caprylic acid-ammonium sulfate methods.
Western blot analysis
HPV16 E6 and HPV16 E7 proteins were produced and
purified using a baculovirus expression system. Fifty
microgram aliquots of total protein were separated on
12% SDS-polyacrylamide gels and transferred onto
nitrocellulose membranes. The membranes were blocked
with TBST buffer containing 5% skim milk and incubated
with AE3 or AG7 mAb (1:1000) overnight. After washing,
the membranes were incubated with horseradish peroxid-
ase-conjugated anti-mouse IgG (Santa Cruz Biotechnology,
Santa Cruz, CA), and the protein bands were visualized by
enhanced chemiluminescence (ECL).
Immunofluorescence
Sf9 cells were infected with HPV recombinant baculovirus
rBacV/HPV16 L1 on coverslips in 6-well plates. Three
days later, the cells were fixed in 10% acetic acid, 50%Figure 1 Immunocompetence of AE3 and AG7 mAbs. A: Western blot
antigens. B: Sf9 cells were inoculated with rBacV/HPV16 L1 in 6-well plates. Th
followed by incubation with FITC-conjugated secondary antibody (1:80). Imm
(×200). C: The images of HPV16L1 VLPs under an immunoelectron microscopethanol, washed with phosphate-buffered saline (PBS) and
then incubated with the mAbs of AE3 and AG7 for 1 h
at 37°C followed by incubation with FITC-conjugated
secondary antibody (1:80) (Invitrogen, USA). The fluor-
escence was detected under an Olympus AX70 epifluor-
escence microscope (Olympus, Tokyo, Japan).Immunoelectron microscopy
HPV16 L1 VLP crude extract was incubated with purified
mAb at 37°C for 1 h and then at 4°C overnight. The mix-
ture was centrifuged at 12,000 g for 90 min, and then the
supernatant was removed. In the negative control, 3%
phosphotungstic acid and 400-mesh high-transmission
nickel grids were used. VLPs were observed under a Hitachi
H600 transmission electron microscope.Hemagglutination inhibition (HI) assay
Red blood cells (RBCs) from BALB/c mice were diluted
in 0.1% BSA-PBS to 1%. Ascites were mixed with the
RBC precipitation of equal volume followed by incubation
at 4°C overnight. The supernatant was collected after cen-
trifugation at 1,000 g for 5 min and then incubated at
56˚C to inactivate the complements. The supernatant was
mixed with HPV16 VLPs of equal volume and loaded into
a 24-well plate followed by incubation at 37°C for 1 h.
Next, 1% RBC of equal volume was added and the mixture
was further incubated for 3 h at room temperature before
evaluating the HI titer.analysis of the specificity of AE3 and AG7 mAbs (1:1000) to different
e supernatant of cultured AE3 and AG7 was incubated for 1 h at 37°C
unofluorescence was detected under an epifluorescence microscope
e. The morphology was indicated by the arrows (×5,000).
Table 1 Comparison of AE3 and AG7 mAbs
AE3 AG7
Titer of ascites 1:106 1:104
Titer of supernatant 1:5120 1:80
Concentration of mAb 148 μg/mL 480 μg/mL
Relative affinity 0.075 μg/mL 0.75 μg/mL
HI titer 1:64 1:8
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The titers of mAbs (AE3 and AG7) in the supernatants
of cultured hybridoma cells and ascites were analyzed by
indirect ELISA. Briefly, ELISA plates were coated with
HPV16L1 protein at 4°C overnight. After washing with
PBS and blocking with 1% BSA, the plates were incu-
bated with serially diluted mAbs followed by incubation
with horseradish peroxidase conjugated anti-mouse IgGFigure 2 Comparison of nucleotides and amino acids of VL between
AE3 and AG7 mAbs. B: Comparison of amino acid of VL between AE3 and
rate of two selected sequences indicated the ratio of different nucleotide ofor 1 h. After washing with PBS, the 3,3′,5,5′-Tetra-
methylbenzidine substrate (100 μl/well; Santa Cruz) was
added followed by incubation for 15 min. The reaction
was stopped by the addition of 1 M HCl (100 μl/well),
and the absorbance was determined at 490 nm.
Sequencing of VH and VL genes
Two hybridoma cell lines (AE3 and AG7) in logarithmic
growth phase were harvested, and total RNA was ex-
tracted with TRIzol (Invitrogen, Carlsbad, CA) according
to the manufacturer’s instructions. cDNA was synthesized
with total RNA and labeled with polyG at the 3′ end of
the RNA using TdT enzyme (Takara, Dalian, China). RT-
PCR was performed using a RT-PCR kit (Takara) and
primers were as follows: for VL gene P1 (5′-CCCCCC
CCCCCCCCC-3′) and P2 (5′-GCGCCGTCTAGAATTA
ACACTCATTCCTGTTGAA-3′); for VH gene P1 (5′-CCAE3 and AG7 mAbs. A: Comparison of nucleotides of VL between
AG7 mAbs. C: Variation rate of VL in AE3 and AG7 mAbs. The variation
r amino acid to total nucleotide or amino acid.
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CAGAGTAATGGTGAGCACATCC-3′). PCR conditions
were denaturation at 95°C for 4 min, 35 cycles of denatur-
ation at 94°C for 40 s, annealing at 55°C for 45 s and
extension at 72°C for 1 min, and a final extension at 72°C
for 7 min. PCR products were purified for sequencing.
The nucleotide and amino acid sequences of AE3 and
AG7 were compared and analyzed using the IgBLAST
software (http://www.ncbi.nlm.nih.gov). Three dimen-
sional (3D) structure prediction was performed using
Geno3D (http://geno3d-pbil.ibcp.fr).
Results
Immunocompetence of AE3 and AG7 mAbs
Western blot analysis showed that AE3 and AG7 mAbs
could specially bind to HPV16 L1 VLP and HPV16 L1
proteins, but not to HPV16 E6 and HPV16 E7 proteins,Figure 3 Comparison of nucleotides and amino acids of VH between
AE3 and AG7 mAbs. B: Comparison of amino acids of VH between AE3 andindicating the specificity of two mAbs (Figure 1A). Immu-
nostaining revealed that AE3 and AE7 could recognize the
virus-infected Sf9 cells (Figure 1B). HPV16 L1 VLPs were
a spherical particle with 55-nm in diameter (Figure 1C).
The HI titer of AE3 and AG7 mAbs was 1:64 and 1:8, re-
spectively. The titers of AE3 and AG7 mAb was 1:5120
and 1:80, respectively, in culture supernatant and 1:106
and 1:104, respectively, in ascites (Table 1).
Detection of VH and VL genes of AE3 and AG7 mAbs
The VL genes of AE3 and AG7 mAbs each included 336
nucleotides (nts) (Figure 2A), and encoded 112 amino
acids (aas) (Figure 2B). The VL had 4 framework regions
(FRs) and 3 complementary-determining regions (CDRs),
and the VL-specific cysteine residues (aa23 and aa93)
located in one of the FRs, in accordance with the
characterization of mouse VL gene. The comparison ofAE3 and AG7 mAbs. A: Comparison of nucleotides of VH between
AG7 mAbs. C: Variation rate of VH of AE3 and AG7 mAbs.
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variation rate of VL in two mAbs was 27.7% at the nt
level, including 29.2% (14/48) in the CDR1, 42.9% (9/21)
in the CDR2, and 48.1% (13/27) in the CDR3. The vari-
ation rate of VL in two mAbs was 39.5% at the aa level, in-
cluding 50% (8/16) in the CDR1, 57.1% (4/7) in the CDR2,
and 66.7% (6/9) in the CDR3. In addition, the CDR2 and
CDR3 regions had higher variation rate (Figure 2C).
The VH genes of AE3 and AG7 mAbs each contained
354 nucleotides (Figure 3A), and encoded 118 amino
acids (Figure3B). Similar to VL, each VH had 4 FRs and 3
CDRs. The VH protein contained 2 characteristic cysteine
residues (aa22 and aa96), consistent with the characteris-
tics of mouse VH gene. The difference in homology be-
tween two mAbs was shown in Figure 3C. The variation
rate of VH regions was 33.3% (118/354) at the nt level,
including 46.7% (7/15) in the CDR1, 27.5% (14/51) in
the CDR2, and 77.8% (21/27) in the CDR3. At the aa
level, the variation rate was 49.2% (58/118), includingFigure 4 Three-dimensional structure prediction of VL and VH of AE3
light chain of AG7 had no α-helix. There were two α-helies (red) at both sid
chain of AG7 (red) were located at the same side.100% (5/5) in the CDR1, 47.1% (8/17) in the CDR2,
and 77.8% (7/9) in the CDR3. The highest variation
rate at nt and aa levels was in the CDR3 for VH genes,
but CDR1 also showed an increased variation rate be-
tween two mAbs (Figure 3C).
3D structure predictions of VL of each mAb showed
an alpha helix in the secondary structure of AE3, which
was absent in AG7. For VH, two alpha helices were pre-
dicted in the secondary structure of AE3 located at two
different sides of the protein, but two alpha helices were
predicted in the secondary structure of AG7 located at
at the same side of the protein (Figure 4).
Discussion and conclusions
In the present study, we constructed and compared two
mABs for HPV16 L1. The immune activity of AE3 mAb
was stronger than that of AG7. In addition, the correlation
between the differences in the biological activity of two
mAbs and their gene sequences was evaluated. CDR3and AG7. The light chain of AE3 mAb had one α-helix (red), but the
es of the heavy chain of AE3 mAb, while the two α-helies of heavy
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which suggested that the corresponding antigens were
relatively complex [12]. The VH of AE3 mAb was rich
in serine, threonine, and asparagine residues, which are
potential glycosylation sites [13]. Although the VH of
AG7 mAb had a greater number of variant amino acids
compared to the VH of AE3 mAb, there were still some
serine, threonine, and asparagine residues in the VH of
AG7 mAb, which may enhance the hydrophilicity and the
affinity of the antibody to corresponding antigen [14].
CDR is an antigen-specific binding site, and anti-
idiotypic antibodies represent their antigenicity. CDR2
and CDR3 not only affect the affinity of antibodies, but
have the functions of FR-1 to assist antibody folding
[12]. Especially, the heavy-chain CDR3 is the site for the
specific binding between antibodies and antigens [15].
In this study, the function of VLs and VHs of two mAbs
was similar, but the amino acids of these 2 regions varied,
especially in the CDRs 1–3. The variation in the nucleo-
tide and amino acid sequences of VL and VH of two
mAbs was rather high in CDR2 and substantially higher in
CDR3. The variation in CDR3, which affects the affinity
(heavy-chain: 77.8%; light-chain: 66.7%), is postulated to
attribute to the main difference between the characteris-
tics of AE3 and AG7. Therefore, the different antigenic
determinants of these two mAbs indicate that the mAbs
target different epitopes.
Comparisons of the spatial structures of similar proteins
showed that the 3D structure of a protein was more con-
servative than the primary structure, but the latter was
more conservative than DNA sequence. Generally, the 3D
structure of a protein determines its function, and the
structure of VH and VL of a specific antibody determines
its affinity and specificity. However, the function of some
antibodies largely depends on the VH, but on the VL to a
lesser extent. No studies have reported the simulated 3D
structure of anti-HPV16 L1 antibodies. In this study, the
homology modeling methods were employed to simulate
the 3D structures of VL and VH of both AE3 and AE7
mAbs. Our results showed that VL structure of AE3 had
more α-helix in the secondary structure compared to that
of AG7; in the VH structure, two α-helies were located at
opposite sides of AG3, while they were located at the same
side of AG7. We hypothesized that the differences in their
structures are related to the different affinity to antigens,
but further studies are required to elucidate the import-
ance of these differences.
For future studies, bioinformatics techniques can be
used to establish the 3D structure of the single-chain vari-
able fragment (scFv) of these mAbs. A scFv model can be
optimized with respect to the mechanical motions and
kinetic parameters to potentially identify the functional
role of each variable region in these mAbs. These studies
will provide a theoretical basis for rationally designinghigh-affinity antibodies for the application in the diagnosis
and treatment of HPV infection.
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